Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation

被引:307
作者
Rodriguez, MS
Desterro, JMP
Lain, S
Lane, DP
Hay, RT
机构
[1] Univ St Andrews, Sch Biol, St Andrews KY16 9ST, Fife, Scotland
[2] Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland
关键词
D O I
10.1128/MCB.20.22.8458-8467.2000
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In normal cells, p53 is maintained at a low level by ubiquitin-mediated proteolysis, but after genotoxic insult this process is inhibited and p53 levels rise dramatically. Ubiquitination of p53 requires the ubiquitin-activating enzyme Ubc5 as a ubiquitin conjugation enzyme and Mdm2, which acts as a ubiquitin protein ligase. In addition to the N-terminal region, which is required for interaction with Mdm2, the C-terminal domain of p53 modulates the susceptibility of p53 to Mdm2-mediated degradation. To analyze the role of the C-terminal domain in p53 ubiquitination, we have generated p53 molecules containing single and multiple lysine-to-arginine changes between residues 370 and 386. Although wild-type (WT) and mutant molecules show similar subcellular distributions, the mutants display a higher transcriptional activity than WT p53. Simultaneous mutation of lysine residues 370, 372, 373, 381, 382, and 386 to arginine residues (6KR p53 mutant) generates a p53 molecule with potent transcriptional activity that is resistant to Mdm2-induced degradation and is refractory to Mdm2-mediated ubiquitination. In contrast to WT p53, transcriptional activity directed by the 6KR p53 mutant fails to be negatively regulated by Mdm2. Those differences are also manifest in HeLa cells which express the human papillomavirus E6 protein, suggesting that p53 C-terminal lysine residues are also implicated in E6-AP-mediated ubiquitination. These data suggest that p53 C-terminal lysine residues are the main sites of ubiquitin ligation, which target p53 for proteasome-mediated degradation.
引用
收藏
页码:8458 / 8467
页数:10
相关论文
共 66 条
  • [21] RB regulates the stability and the apoptotic function of p53 via MDM2
    Hsieh, JK
    Chan, FSG
    O'Connor, DJ
    Mittnacht, S
    Zhong, S
    Lu, X
    [J]. MOLECULAR CELL, 1999, 3 (02) : 181 - 193
  • [22] ALLOSTERIC ACTIVATION OF LATENT P53 TETRAMERS
    HUPP, TR
    LANE, DP
    [J]. CURRENT BIOLOGY, 1994, 4 (10) : 865 - 875
  • [23] REGULATION OF THE SPECIFIC DNA-BINDING FUNCTION OF P53
    HUPP, TR
    MEEK, DW
    MIDGLEY, CA
    LANE, DP
    [J]. CELL, 1992, 71 (05) : 875 - 886
  • [24] RESCUE OF EMBRYONIC LETHALITY IN MDM2-DEFICIENT MICE BY ABSENCE OF P53
    JONES, SN
    ROE, AE
    DONEHOWER, LA
    BRADLEY, A
    [J]. NATURE, 1995, 378 (6553) : 206 - 208
  • [25] KASTAN MB, 1991, CANCER RES, V51, P6304
  • [26] p53: Puzzle and paradigm
    Ko, LJ
    Prives, C
    [J]. GENES & DEVELOPMENT, 1996, 10 (09) : 1054 - 1072
  • [27] The carboxy-terminus of I kappa B alpha determines susceptibility to degradation by the catalytic core of the proteasome
    Kroll, M
    Conconi, M
    Desterro, MJP
    Marin, A
    Thomas, D
    Friguet, B
    Hay, RT
    Virelizier, JL
    ArenzanaSeisdedos, F
    Rodriguez, MS
    [J]. ONCOGENE, 1997, 15 (15) : 1841 - 1850
  • [28] Regulation of Mdm2-directed degradation by the C terminus of p53
    Kubbutat, MHG
    Ludwig, RL
    Ashcroft, M
    Vousden, KH
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (10) : 5690 - 5698
  • [29] An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs
    Laín, S
    Midgley, C
    Sparks, A
    Lane, EB
    Lane, DP
    [J]. EXPERIMENTAL CELL RESEARCH, 1999, 248 (02) : 457 - 472
  • [30] Cancer - Awakening angels
    Lane, D
    [J]. NATURE, 1998, 394 (6694) : 616 - 617